MVA-BN Vaccine Effectiveness: A Systematic Review of Real-World Evidence in Outbreak Settings

Lauren M.K. Mason; Estefania Betancur; Margarita Riera-Montes; Florian Lienert; Suzanne Scheele

doi:10.1101/2024.04.25.24306078

Abstract

Background Mpox is a disease endemic to Central and West Africa. It caused outbreaks in non-endemic countries, mainly in 2022. The endemic Democratic Republic of Congo is currently experiencing its largest outbreak yet. The vaccine Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) is approved for active immunization against mpox and smallpox. Since the outbreak in 2022, real-world studies have assessed MVA-BN’s vaccine effectiveness (VE) against mpox, and this systematic literature review aims to summarize the most current evidence.

Methods Medline (via PubMed), Embase, and LILACS were searched, as well as grey literature sources and publications’ bibliographies to identify observational studies published between 1/Jan/2022 and 28/Feb/2024 that estimate the VE of MVA-BN against symptomatic mpox or provide risk measures that allow calculation of these VE estimates. Data were presented descriptively in tables and text; the methodological quality of included records was assessed using an informal qualitative approach.

Results The literature search identified a total of 16 records that fit the inclusion criteria. The studies took place in high-income countries and were heterogenous in design, setting, and definition of at-risk populations. MVA-BN VE estimates against symptomatic mpox infection ≥14 days post-vaccination were assessed. Where the study population was exclusively or primarily those receiving pre-exposure prophylactic vaccination, the adjusted VE estimates ranged from 35% to 86% (n=8 studies) for one dose and from 66% to 90% (n=5) for two doses. Where only post-exposure prophylactic vaccination was assessed, adjusted VE estimates were reported for one dose only at 78% and 89% (n=2). Additionally, MVA-BN reduced the risk of mpox-related hospitalization in one study and the severity of mpox clinical manifestations in two studies.

Conclusions Despite heterogeneity in study design, setting, and at-risk populations, the reported VE estimates against symptomatic mpox infection for one or two doses of MVA-BN support deployment of MVA-BN for mpox outbreak control.

Competing Interest Statement

FL and SS are employees of Bavarian Nordic. The study-related activities of P95 employees EB, LM, and MRM were funded by Bavarian Nordic. All authors attest that they meet the ICMJE criteria for authorship.

Funding Statement

The research presented in this manuscript and manuscript development were funded by Bavarian Nordic Inc.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes